【Video】Professor Xu Ruihua's "Chinese Plan" for the treatment of nasopharyngeal cancer is internationally recognized

In the early morning of June 7, Xu Ruihua, director and dean of Sun Yat-sen University Cancer Center, was invited to attend the plenary meeting of the American Society of Clinical Oncology (ASCO) online and gave a report, introducing the "Chinese Plan" for the treatment of nasopharyngeal cancer
.

This is also the world's first multi-center, randomized, double-blind, placebo-controlled phase III clinical study of anti-PD-1 monoclonal antibody for the treatment of recurrent or metastatic nasopharyngeal carcinoma
.

Professor Ruihua Xu’s report at the (ASCO) annual meeting is "JUPITER-02: A comparison of terreprizumab or placebo combined with gemcitabine and cisplatin in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
He is also the chief scientist of this research
.

"Compared with some other types of cancer, the treatment of advanced nasopharyngeal carcinoma has fallen behind, but the results of the JUPITER-02 study have brought new hopes for patients to improve the efficacy, and will also change our treatment of nasopharyngeal carcinoma
.

Commented by Dr.
Julie R.
Gralow, Chief Medical Officer of ASCO
.

In the fields of high-incidence tumors in China, such as nasopharyngeal cancer, esophageal cancer, and gastric cancer, the research and development of new drugs for such tumors in European and American countries has been in a blank for a long time
.

The "China Plan" researched by Xu Ruihua's team is expected to rewrite the global treatment standards for nasopharyngeal cancer
.